TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06613295

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: SABR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR
Study: NCT06559007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5041 dose level 2
Description: Single dose of HRS-5041 orally administered
Study: NCT06149520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250
Description: Dose 1 or dose 2 of BAY3018250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250
Description: Dose 1 or dose 2 of BAY3018250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY3018250
Description: Matching placebo to BAY3018250
Study: NCT06613295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Separation surgery
Description: Separation surgery
Study: NCT06611995

Intervention type: OTHER
Intervention: observational study
Description: Observational study without intervention

Intervention type: OTHER
Intervention: observational study
Description: Observational study without intervention
Study: NCT06611852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout.~Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes.~Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core.~Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic cupping therapy in addition to aerobic exercise
Description: Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential therapy in addition to aerobic exercise
Description: interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential therapy, electronic cupping therapy in addition to aerobic exercises
Description: interferential therapy, electronic cupping therapy in addition to aerobic exercises
Study: NCT06613113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease progression or intolerable toxicity occurred.
Study: NCT06611449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The minimal flow anesthesia with sevoflurane group
Description: In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The high flow anesthesia with sevoflurane group
Description: Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery.
Study: NCT06612593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The patient will receive 2 tablets twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
Study: NCT05641844

Intervention type: DEVICE
Group type: OTHER
Intervention: RD2 Ver.02
Description: Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.

Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.

Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
Study: NCT06333886

Intervention type: DEVICE
Intervention: Sacral electromyography
Description: Assessment of neuro-sacral function using point-of-care sacral surface electromyography
Study: NCT04720989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bathing With Baby Cleanser and water
Description: Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bathing With only Water
Description: Preterm infants will have their first baths only with water.
Study: NCT05758818

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (positive control)
Description: Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2
Study: NCT05602740

Intervention type: DEVICE
Intervention: Harmony
Description: Passive recording of the head pulse
Study: NCT06134661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS (continuous Theta Burst Stimulation)
Description: Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 1500 pulses per session.
Study: NCT06007846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda
Description: Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
Study: NCT04961164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Potato Starch, Corn Starch
Description: Consume resistant potato starch at study period 1, then consume corn starch at study period 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn Starch, Resistant Potato Starch
Description: Consume corn starch at study period 1, then consume resistant starch at study period 2.
Study: NCT04940663

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMA
Description: Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
Study: NCT06239610

Intervention type: DEVICE
Group type: OTHER
Intervention: electromagnetic placement device
Description: Daily use of an EMPD to verify FT position
Study: NCT05062746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-Rhythm Therapy
Description: One session Matrix-Rhythm Therapy will be applied to affected body parts.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy and rehabilitation
Description: Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
Study: NCT06437509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT04643327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
Study: NCT04692675

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: 3T endorectal coil MR imaging of the prostate gland
Study: NCT06474572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope and table at xiphoid level
Description: Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope and table at xiphoid level
Description: Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope and table at umbilical level
Description: Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope and table at umbilical level
Description: Participants will be required to intubate the manikin with a videolaryngoscope and table at umbilical level
Study: NCT04862234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (CGM), blinded
Description: Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous glucose monitor (CGM), blinded
Description: Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
Study: NCT06254443

Intervention type: OTHER
Group type: OTHER
Intervention: Enema Bowel preparation
Description: Enema Group (Experimental Group): Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.

Intervention type: OTHER
Group type: OTHER
Intervention: PEG Bowel preparation
Description: Oral PEG Group (Control Group): Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
Study: NCT05986552

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Schema Therapy (IST)
Description: IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-Group Schema Therapy (IGST)
Description: IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
Study: NCT06017258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD371-specific/YSNVz/I-18 CAR T cells
Description: Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD371-specific/YSNVz/I-18 CAR T cells
Description: Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD371-specific/YSNVz/I-18 CAR T cells
Description: Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.
Study: NCT06414954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets taken twice a day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets taken twice a day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets taken twice a day for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken twice a day for 21 days
Study: NCT06576648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Healthy Choices (mHC)
Description: mHC is a four-session, 20-minute, motivational interviewing-based intervention, which will be delivered on the CIAS platform. It will be tailored to participants' responses given during the interaction in the intervention. In the first two sessions, the (virtual) counselor will motivate participants to overcome stigma and utilize HIV prevention services by using tailored motivational interviewing strategies, develop an individualized change goal based on their readiness, and provide cognitive behavioral strategies. In the last two sessions, the counselor will review the change plan, monitor progress, and provide support for sustained behavioral change. The sessions will occur within three months after baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Healthy Choices (mHC)
Description: mHC is a four-session, 20-minute, motivational interviewing-based intervention, which will be delivered on the CIAS platform. It will be tailored to participants' responses given during the interaction in the intervention. In the first two sessions, the (virtual) counselor will motivate participants to overcome stigma and utilize HIV prevention services by using tailored motivational interviewing strategies, develop an individualized change goal based on their readiness, and provide cognitive behavioral strategies. In the last two sessions, the counselor will review the change plan, monitor progress, and provide support for sustained behavioral change. The sessions will occur within three months after baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Finding Respect and Ending Stigma around HIV (FRESH)
Description: FRESH content includes six 10-15 minute sessions with interactive, culturally sensitive multimedia modules, which will be delivered on the CIAS platform. The content will aim to improve self-efficacy, reduce intersectional stigmas and promote HIV preventative behaviors. The sessions will occur within three months after baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Finding Respect and Ending Stigma around HIV (FRESH)
Description: FRESH content includes six 10-15 minute sessions with interactive, culturally sensitive multimedia modules, which will be delivered on the CIAS platform. The content will aim to improve self-efficacy, reduce intersectional stigmas and promote HIV preventative behaviors. The sessions will occur within three months after baseline.
Study: NCT06548854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 Injection/STC314 Injection Placebo
Description: All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STC314 Injection/STC314 Injection Placebo
Description: All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 Injection/STC314 Injection Placebo
Description: All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
Study: NCT04407039

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.

Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.
Study: NCT06576648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard PrEP Counseling
Description: All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard PrEP Counseling
Description: All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard PrEP Counseling
Description: All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard PrEP Counseling
Description: All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.